MedTrace Logo

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

NCT07185945 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-05-18

No results posted yet for this study

Summary

This is a Phase II, single arm study. All subjects will receive Zanzalintinib 60 mg orally once daily until progression per RECIST 1.1 or intolerable toxicities or patient/investigator decision to discontinue study therapy. Radiology imaging will be performed every 8 weeks for 3 timepoints then every 12 weeks thereafter. A window of ± 7 days may be applied to all study visits to accommodate observed holidays, inclement weather, scheduling conflicts etc.

Conditions

  • Advanced Urothelial Carcinoma

Interventions

DRUG

Zanzalintinib

60 mg orally once daily

Sponsors & Collaborators

  • Exelixis

    collaborator INDUSTRY

  • Advent Health

    collaborator UNKNOWN

  • Guru Sonpavde

    lead OTHER

Principal Investigators

  • Guru Sonpavde, MD · Advent Health Orlando

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-06-30
Completion
2029-06-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185945 on ClinicalTrials.gov